New Delhi, Jan 27 () Drug firm Wockhardt on Monday for the first time in three years reported a consolidated net profit of Rs 19.21 crore for the December 2019 quarter mainly on account of improvement in operational performance and cost rationalisation.
The company had posted a net loss of Rs 76.86 crore for the corresponding period of 2018-19, Wockhardt said in a filing to the BSE.
Consolidated revenue from operations stood at Rs 869.15 crore for the quarter under consideration. It was Rs 1,045.86 crore for the same period year ago.
While the company has been reporting steady EBITDA quarter by quarter, for the first time in the past 3 years, the company has bounced back into profit owing to marked improvement in operational performance and cost rationalisation, Wockhardt said.
Total expenses stood at Rs 869.93 crore for the quarter under consideration. It was Rs 1,168.53 crore for the same period year ago.
In January 2020, Drug Controller General of India (DCGI) approved the company's two new antibiotics, EMROK (IV) and EMROK 0 (Oral), for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteraemia, it added.
The company's continued pursuit in creating strong intellectual property (IP) base resulted into filing of 5 patents during the quarter ended on December 31, 2019, taking the cumulative filings to 3,162, Wockhardt said.
Wockhardt was granted 9 patents during the quarter and now holds 717 patents, it added.
Shares of Wockhardt Ltd closed at Rs 352.90 per scrip on BSE, up 18.01 per cent over previous close. AKT RUJ RUJ
Next Story
Global stocks rally even as Sensex, Nifty fall sharply on Friday
In second consecutive week of decline, forex kitty drops $2.28 bn to $640.33 bn
SBI Life Q4 profit rises 4% to ₹811 crore
IMD predicts severe heatwave conditions over East, South Peninsular India for next five days
COVID lockdown-related school disruptions will continue to worsen students’ exam results into the 2030s: study
